New Small-Molecule Synthetic Antimycobacterials
Copyright policy )New Small-Molecule Synthetic Antimycobacterials
Drugs for treating tuberculosis (TB) have been available for over half a century, and yet the incidence of disease worldwide continues to rise year by year. In 2002, the last year for which statistics are available, it is estimated that 24,000 people developed active disease and close to 5,000
- GlaxoSmithKline (United Kingdom) United Kingdom
- University of Manchester United Kingdom
- University of East Anglia United Kingdom
- University of Manchester United Kingdom
- Cellzome, GSK, Middlesex, UK.
Molecular Structure, ResearchInstitutes_Networks_Beacons/manchester_institute_of_biotechnology; name=Manchester Institute of Biotechnology, Manchester Institute of Biotechnology, Drug Design, Antitubercular Agents, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis
Molecular Structure, ResearchInstitutes_Networks_Beacons/manchester_institute_of_biotechnology; name=Manchester Institute of Biotechnology, Manchester Institute of Biotechnology, Drug Design, Antitubercular Agents, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).159 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!